Crown BioScience experts explore organoid models and high-content imaging to evaluate T-cell-targeted therapies and ...

Both studies, which are reporting the results of early-stage clinical trials, show that the interventions were safe, and that ...

New research zeroes in on a unique group of immune cells that could transform how we treat—and possibly prevent—severe food ...

Delve into the landscape of biotech companies developing treatments for HIV and find out if we are getting closer to a cure.

A team of researchers has successfully created more effective immune cells that can fight cancer without damaging healthy ...

The cells were also found to require the proteins Retinoic Acid-Related Orphan Receptor-gamma-t (RORγt) and PR domain-containing 16 (Prdm16) to effectively protect tolerated proteins from the ...

T-cells are collected from the patient’s blood. In a lab, these T-cells are genetically modified to express a special receptor (CAR) that targets cancer cells. The modified CAR-T cells are grown ...

Lyell Immunopharma (LYEL) announced that the U.S. Food and Drug Administration granted Regenerative Medicine Advanced Therapy, RMAT, ...

Along with GC012F, Gracell’s pipeline includes a dual-targeting CAR-T for acute myelogenous leukaemia (AML), a CD19/CD7 therapy for B-cell acute lymphoblastic leukaemia (B-ALL), and BCMA/CD7 ...

Bats are a reservoir for many pathogens that can infect humans and domestic animals, yet we lack effective tools to study bat ...

Post April 7 - Lyell Immunopharma: Less than a year after purchasing private cell therapy company ImmPact Bio, CAR-T developer Lyell plans to lay off 73 employees at ImmPact’s manufacturing ...